Diabetic Retinopathy Trial: Contrast Sensitivity Endpoint

Here’s a breakdown of teh provided text,summarizing the⁢ key information:

Main Topic: A new ⁤trial (MAGIC trial) investigating contrast sensitivity as a functional test in patients with nonproliferative diabetic retinopathy (NPDR) ⁤and retinal⁢ nonperfusion.

Key People: Dante ⁢J. Pieramici, MD

Trial Details (MAGIC Trial):

purpose: To assess the impact of Vabysmo (faricimab) on retinal nonperfusion.
Design: Randomized trial.
Arms:
Monthly Vabysmo for 1 year, then quarterly treatments. Observation for 1 year, then faricimab⁣ in the second year.
Primary Endpoint: Change in area of‍ retinal nonperfusion (measured by optos widefield angiography).

why Contrast sensitivity Matters:

⁤ Conventional visual acuity tests may not detect problems until ⁢diabetic retinopathy is advanced.
Contrast sensitivity is a more effective functional endpoint‍ as it can detect subtle vision changes earlier.
* New methods allow⁣ for quick and effective measurement of contrast sensitivity.

Source: Presentation by Dante ⁣J. pieramici at ⁢Clinical Trials at the ⁤Summit (June 21,2025,Las Vegas).

Disclosure: Healio could not confirm any relevant financial disclosures for the speaker⁣ at the time of ‍publication.